Nothing Special   »   [go: up one dir, main page]

FI20041129A0 - Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi - Google Patents

Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi

Info

Publication number
FI20041129A0
FI20041129A0 FI20041129A FI20041129A FI20041129A0 FI 20041129 A0 FI20041129 A0 FI 20041129A0 FI 20041129 A FI20041129 A FI 20041129A FI 20041129 A FI20041129 A FI 20041129A FI 20041129 A0 FI20041129 A0 FI 20041129A0
Authority
FI
Finland
Prior art keywords
thioxothiazolidinone
drugs
compounds
thioxothiazolidinone compounds
Prior art date
Application number
FI20041129A
Other languages
English (en)
Swedish (sv)
Inventor
Mikael Bjoerklund
Erkki Koivunen
Original Assignee
Ctt Cancer Targeting Tech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctt Cancer Targeting Tech Oy filed Critical Ctt Cancer Targeting Tech Oy
Priority to FI20041129A priority Critical patent/FI20041129A0/fi
Publication of FI20041129A0 publication Critical patent/FI20041129A0/fi
Priority to US11/661,505 priority patent/US20080108677A1/en
Priority to JP2007528899A priority patent/JP2008511594A/ja
Priority to PCT/FI2005/050305 priority patent/WO2006024699A1/en
Priority to EP05778166A priority patent/EP1789406A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI20041129A 2004-08-30 2004-08-30 Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi FI20041129A0 (fi)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FI20041129A FI20041129A0 (fi) 2004-08-30 2004-08-30 Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
US11/661,505 US20080108677A1 (en) 2004-08-30 2005-08-30 Thioxothiazolidinone Compounds For Use As Pharmaceuticals
JP2007528899A JP2008511594A (ja) 2004-08-30 2005-08-30 医薬品として使用するチオキソチアゾリジノン化合物
PCT/FI2005/050305 WO2006024699A1 (en) 2004-08-30 2005-08-30 Thioxothiazolidinone compounds for use as pharmaceuticals
EP05778166A EP1789406A1 (en) 2004-08-30 2005-08-30 Thioxothiazolidinone compounds for use as pharmaceuticals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20041129A FI20041129A0 (fi) 2004-08-30 2004-08-30 Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi

Publications (1)

Publication Number Publication Date
FI20041129A0 true FI20041129A0 (fi) 2004-08-30

Family

ID=32922140

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20041129A FI20041129A0 (fi) 2004-08-30 2004-08-30 Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi

Country Status (5)

Country Link
US (1) US20080108677A1 (fi)
EP (1) EP1789406A1 (fi)
JP (1) JP2008511594A (fi)
FI (1) FI20041129A0 (fi)
WO (1) WO2006024699A1 (fi)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044817A1 (en) 2003-11-05 2005-05-19 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2009543874A (ja) * 2006-07-18 2009-12-10 ユニバーシティー オブ ロチェスター チアゾリジノン誘導体
WO2008082537A2 (en) 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
EP2278879B1 (en) 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131951A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
KR101018791B1 (ko) 2008-08-04 2011-03-03 한국생명공학연구원 세포외 신호조절 키나제의 활성을 저해하는타이오옥소-타이아졸리딘-온 유도체 또는 이의 약학적으로허용가능한 염을 유효성분으로 함유하는 암 또는 심혈관계질환의 예방 또는 치료용 조성물
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
WO2011160024A2 (en) * 2010-06-17 2011-12-22 Fuzians Biomedicals, Inc. Compounds useful as antiviral agents, compositions, and methods of use
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
JP6014816B2 (ja) 2011-05-10 2016-10-26 国立大学法人神戸大学 Ｒａｓ機能阻害作用を有するチオキソチアゾリジン誘導体
KR101319593B1 (ko) 2011-07-19 2013-10-16 한국과학기술연구원 메틸리덴-헤테로싸이클릭 화합물
AU2013248972A1 (en) 2012-04-20 2014-11-13 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
JP2018521121A (ja) 2015-06-12 2018-08-02 アドハエア ファーマシューティカルズ，インコーポレイティド （ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
CN110573499B (zh) 2017-02-28 2023-04-21 莫菲克医疗股份有限公司 αvβ6整合蛋白的抑制剂
CN112805001B (zh) 2018-08-29 2024-07-23 莫菲克医疗股份有限公司 抑制αvβ6整联蛋白
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7684798A (en) * 1997-05-30 1998-12-30 Texas Biotechnology Corporation Compounds that inhibit the binding of vascular endothelial growth factor to its receptors
AU6330999A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU3111700A (en) * 1998-12-04 2000-06-19 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
JP2003507473A (ja) * 1999-07-01 2003-02-25 ジェロン コーポレイション テロメラーゼインヒビターおよびその使用の方法
US20050042674A9 (en) * 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
US20040214872A1 (en) * 2002-09-26 2004-10-28 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US20060276520A1 (en) * 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
WO2005007141A2 (en) * 2003-07-11 2005-01-27 Proteologics, Inc. Ubiquitin ligase inhibitors and methods related thereto
US20060106077A1 (en) * 2003-07-18 2006-05-18 Pintex Pharmaceuticals, Inc. Pin1-Modulating compounds and methods of use thereof
WO2005074375A2 (en) * 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2008511594A (ja) 2008-04-17
WO2006024699A1 (en) 2006-03-09
EP1789406A1 (en) 2007-05-30
US20080108677A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
LTPA2017005I1 (lt) Nauji junginiai, kaip opioido receptoriaus moduliatoriai
NL1029015A1 (nl) Therapeutische verbindingen.
ATE477257T1 (de) Piperidinylamino-thienoä2,3-dü- pyrimidinverbindungen
DK2041139T3 (da) Farmaceutiske forbindelser
DK1817309T3 (da) Acetamidforbindelser som fungicider
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
DE602005026188D1 (de) Medikamentenspender
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
FI20041129A0 (fi) Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
BRPI0810646A2 (pt) " compostos farmacêuticos ".
DK1753764T3 (da) Pyrrolopyridin-derivater
ITMO20050343A1 (it) Supporto per medicazione
ATE404546T1 (de) Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
ITMI20042238A1 (it) Composti per fluoropolirterei
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
NO20034952D0 (no) Farmasöytiske forbindelser
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
ATE384719T1 (de) Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen
SE0400022D0 (sv) New compounds
SE0400254D0 (sv) New compounds
FI20040136A0 (fi) Erityisesti diabeetikoille soveltuvia koostumuksia
SE0402678D0 (sv) Pharmaceutical use
SE0402639D0 (sv) Pharmaceutical use
SE0402638D0 (sv) Pharmaceutical use

Legal Events

Date Code Title Description
FD Application lapsed